AB Science's Loan Repayment Terms Renegotiation
AB Science SA today announced significant advancements in its financial restructuring efforts, aimed at providing the company with enhanced flexibility to focus on its core operations. An agreement in principle has been reached with financial creditors to postpone loan repayments for a duration of 24 months, specifically addressing obligations related to approximately 3.7 million euros in bank debt.
Key Features of the Agreement
This new repayment structure allows AB Science to allocate savings into crucial areas, particularly research and development. The agreement hinges on a pivotal condition—the postponement of the repayment terms for a loan obtained from the European Investment Bank (EIB).
Specific Loan Modifications
The key aspects of the loan renegotiation include the freezing of principal repayments on state-guaranteed loans amounting to 3.5 million euros from January 1, 2025, until December 31, 2026. Amortization is set to recommence on January 1, 2027, further extending the repayment period up until March 31, 2029.
Financial Strategy for Innovation
In parallel, AB Science has highlighted a similar strategy for an innovation loan of 0.2 million euros. This plan includes postponing principal repayments until September 30, 2025, with renewed amortization commencing shortly thereafter. These initiatives exemplify AB Science's commitment to maintaining a robust pipeline for innovation while strategically managing its financial commitments.
Importance of Creditors' Support
The agreement signals strong support from creditors, reflecting a shared commitment to the company's long-term success. Throughout the negotiation phase, creditors provided a standstill arrangement that allowed AB Science to focus on its operational priorities without immediate financial pressure.
Ongoing Discussions with EIB
AB Science is actively engaged in talks with the EIB regarding the postponement of a significant loan repayment deadline. The original terms required repayments to commence in January and December of 2028 for a loan totaling 12 million euros. However, the company is optimistic about reaching an agreement that aligns with its restructuring goals.
Overview of AB Science
Founded in 2001, AB Science is at the forefront of pharmaceutical innovation, specializing in the research and development of protein kinase inhibitors (PKIs). These medications target critical signaling pathways within cells, addressing diseases that present significant challenges in treatment. The lead compound, masitinib, is already approved for veterinary use and is being developed for human use in various conditions, including oncology and neurological disorders.
The company's corporate strategies underscore its dedication to addressing high unmet medical needs. Headquartered in Paris, AB Science is listed on Euronext Paris under the ticker AB. The pursuit of innovative solutions remains a central focus as the company navigates its evolving financial landscape.
Frequently Asked Questions
What agreement has AB Science reached with its creditors?
AB Science has agreed to postpone loan repayments for 24 months, aimed at strengthening its R&D initiatives.
How will the postponed repayments affect AB Science's operations?
The company intends to reinvest the savings from postponed repayments into research and development to bolster innovation.
What are the key conditions of the loan restructuring?
The restructuring involves freezing principal repayments and extending the loan terms, conditional upon postponement of the EIB loan repayment.
What is the main focus of AB Science?
AB Science focuses on the development of protein kinase inhibitors for treating serious diseases and aims to contribute to significant medical advancements.
Where is AB Science located?
AB Science is headquartered in Paris, France, and is publicly traded on Euronext Paris as AB.
